Tissue-resident memory B cells (BRM) are established contributors to localized protection in barrier tissues against microbial challenge. The study profiled B cells collected from patients with colorectal cancer and cutaneous basal cell carcinoma and identified a memory B cell subset expressing CD69, a marker consistent with a tissue-resident phenotype. These CD69+ memory B cells were found among tumor-infiltrating B-cell populations, supporting the presence of BRM-like cells within solid tumors rather than exclusively in classical barrier tissues.
The identification relied on transcriptional and phenotypic profiling of tumor-associated B cells. The authors interpret CD69 expression together with other memory-associated features as consistent with a tissue-resident memory identity for this intratumoral subset.
To assess whether the BRM-like phenotype in tumors reflects a broader program, the investigators performed an integrative analysis of transcriptomic datasets. From these data they derived an optimized BRM signature—a set of genes and expression features that characterize the tissue-resident B cell state observed in the primary tumor samples.
This optimized signature was reported to be enriched across multiple cancer types in the datasets examined, indicating that a conserved BRM transcriptional program may be present in diverse tumor settings. The enrichment across cancers suggests that tumor-associated BRM-like populations are not restricted to the skin or colon but could represent a general component of the tumor immune microenvironment.
Functional characterization of the tumor-infiltrating BRM-like cells indicated a preferential autoreactivity. In other words, these BRM-like B cells displayed reactivity biased toward self-antigens associated with tumors rather than classical foreign antigens. The source reports this as a distinguishing feature of tumor-resident BRM, suggesting that their antigen specificity may center on tumor-associated self epitopes.
This finding positions BRM as potentially tuned to recognize tumor-associated alterations in self rather than pathogen-derived targets, which has implications for how these cells contribute to local immune surveillance and effector mechanisms in the tumor microenvironment.
The study examined the relationship between the BRM transcriptional signature and clinical correlates in available datasets. The BRM signature correlated with patient outcomes and with response to immunotherapy in the cohorts analyzed. These associations suggest that the presence or activity of BRM-like cells within tumors may influence prognosis and the efficacy of immune-based therapies.
Because the work is based on profiling and associative analyses, the authors present these correlations as hypothesis-generating; causality between BRM presence and clinical benefit was not claimed in the source and would require further validation.
To test whether localized BRM can be established experimentally and whether they influence tumor control, the investigators used murine models with organ-targeted vaccination. Vaccination directed to the skin or lung generated localized BRM populations in the respective organs, demonstrating that tissue-targeted immunization can seed resident memory B cells at sites relevant for tumor challenge.
These preclinical experiments aimed to model how vaccination strategies might elicit protective BRM in tissues at risk for tumor development or metastasis.
When mice with vaccine-induced localized BRM were challenged with tumors in the targeted organs, the presence of BRM provided organ-specific protection against tumor growth. Crucially, this protective effect depended on IgA, indicating that IgA antibody effector function mediated, at least in part, the local anti-tumor activity of BRM.
The dependence on IgA aligns with known roles of IgA in mucosal and barrier tissue immunity and suggests that BRM may leverage IgA-mediated mechanisms to limit tumor establishment or progression in tissue niches where BRM reside.
Collectively, the data establish tumor-associated BRM as an active component of local anti-cancer immunity, characterized by a CD69+ tissue-resident phenotype, an optimized transcriptional signature present across cancers, preferential autoreactivity to tumor-associated self-antigens, and the ability to mediate IgA-dependent organ-specific tumor protection in preclinical models.
These results raise several potential clinical and translational avenues: using the BRM signature as a biomarker for prognosis or immunotherapy response, exploring vaccination approaches to elicit protective BRM at tumor-prone sites, and dissecting the antigen specificity and effector mechanisms of BRM in human cancers. The source indicates that BRM preferentially react to tumor-associated self-antigens, but detailed antigen repertoires, mechanistic pathways, and causal impacts on therapy outcomes require additional study.
This work is reported as a preprint and has not been peer reviewed. The source declares no competing interests and lists funding sources in the original document. Readers should interpret the findings in the context of preprint status and await further validation through peer review and follow-up studies.